Introducing Allē Payment Plans, Powered by Cherry
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has launched Allē Payment Plans, allowing patients to pay for aesthetic treatments over time without hard credit checks. This initiative aims to make treatments like BOTOX® Cosmetic and JUVÉDERM® more accessible. Market research indicates that while over 50 million Americans are interested in facial injectables, cost remains a major barrier, with only a fraction seeking treatment annually. The pilot program showed that 54% of transactions were from new patients, and 34% included multiple brands. The national rollout of the payment plans begins today, with full availability expected in the coming months. The plans are offered at no cost to aesthetic providers for Allergan Aesthetics products, enhancing their ability to attract new patients.
- Launch of Allē Payment Plans to make aesthetic treatments more accessible.
- 54% of transactions in the pilot program were from new patients.
- 34% of transactions included multiple brands.
- No cost to aesthetic providers for Allergan Aesthetics products.
- None.
Insights
**Overview of Market Dynamics:** The introduction of Allē Payment Plans taps into a well-documented market need. Market research indicates that more than
**Potential Market Expansion:** The pilot program's data suggests significant potential for market expansion. With
**Competitive Positioning:** Allergan Aesthetics, known for leading products like BOTOX® and JUVÉDERM®, is strengthening its competitive position through innovative financing solutions. This move could also set a precedent within the industry, possibly prompting competitors to offer similar options. For investors, this indicates a proactive strategy from Allergan Aesthetics to maintain and potentially grow its market leadership.
**Revenue Growth Implications:** The introduction of Allē Payment Plans at no cost to aesthetic practices for eligible Allergan Aesthetics treatments and products suggests potential for increased revenue streams. By eliminating the upfront cost barrier for consumers and practices, more patients might opt for treatments, increasing sales volume and, consequently, revenues.
**Cash Flow Considerations:** While this payment plan introduces a deferred payment model, the impact on Allergan's cash flow appears mitigated. By partnering with Cherry, they likely ensure immediate payouts for participating practices, with Cherry assuming the risk of consumer default. This strategy could contribute to a stable cash flow while expanding market reach.
**Operational Efficiency:** The integration of payment plans through Allē could streamline office operations. Practices may see reduced financial administration burdens, potentially lowering operational costs and improving profit margins. For investors, this operational efficiency can translate into better financial health for the company and higher profitability.
- Allē Members Enjoy the Aesthetic Treatments They Love Today, and Pay Over-Time with No Hard Credit Checks
- Participation Comes at No Cost* to Aesthetic Providers for Allergan Aesthetics Treatments and Products, Increasing Affordability of Treatments with Flexible Payment Options
Market research shows more than 50 million Americans are interested in facial injectables, but only a fraction seek treatment each year, citing cost as the biggest barrier1. Now, with Allē Payment Plans, patients can pay for their treatments with a monthly plan making it easier for them to achieve their aesthetic goals.
"We are excited to debut flexible payment plans within Allē at no cost* to aesthetic practices for Allergan Aesthetics treatments and products, increasing the accessibility and affordability of aesthetic treatments for patients and supporting providers to welcome new patients," said Jasson Gilmore, Senior Vice President,
Allē Payment Plans initial pilot program uncovered key insights. "We found that
The Allē Payment Plans national roll-out begins today, with full availability across the
"We are thrilled to partner with Allergan Aesthetics, the market leader, given their industry defining products and their success with Allē, the country's leading aesthetics loyalty rewards platform," said Sean Schroeder, COO at Cherry. "With Cherry's years of experience in patient financing, and Allē's leadership in aesthetics rewards, this combined offering will support practices in helping make aesthetics treatments more accessible for all."
Allē is offering an inside look of Allē Payment Plans to providers attending The Aesthetic Show (TAS) in
In serving more than seven million Members across ~30,000 practices to date, part of Allē's mission is to help educate consumers about aesthetic treatments, and to simplify office operations for practices. From its inception, Allē has disrupted the aesthetics industry by offering the most robust rewards program. Allē is the first and only loyalty program in the aesthetics market to also offer consumers the ability to earn points on over 50 non-Allergan Aesthetics treatments and brands. By providing Members with information, tools, and incentives, and now with flexible ways to pay, Allē empowers consumers along their treatment journey, making the next product purchase or treatment closer within reach.
To learn more about offering Allē Payment Plans in your practice, please reach out to your Allergan Aesthetics sales representative, or visit http://business.alle.com/payment-plans for more information.
*Payouts in full are for eligible Allergan Aesthetics products and treatments only. All other services are subject to standard Cherry rates.
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
About Cherry
Cherry's mission is to help medical providers treat more patients by offering the best payment plan solution with high approvals, low cost, and a seamless experience. With leading financing terms for practices and patients, Cherry is the preferred partner for over 20,000 practices in aesthetics, dental and beyond. For more information, visit www.withcherry.com.
BOTOX® COSMETIC IMPORTANT SAFETY INFORMATION AND APPROVED USES
Approved Uses
BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, and frown lines between the eyebrows in adults.
IMPORTANT SAFETY INFORMATION
BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:
- Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.
- Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.
BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.
There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, and/or forehead lines.
BOTOX® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of taking BOTOX® Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities.
Serious and/or immediate allergic reactions have been reported. They include: itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or faint.
Do not receive BOTOX® Cosmetic if you: are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc® (rimabotulinumtoxinB), Dysport® (abobotulinumtoxinA), or Xeomin® (incobotulinumtoxinA); have a skin infection at the planned injection site.
Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects including difficulty swallowing and difficulty breathing from typical doses of BOTOX® Cosmetic.
Tell your doctor about all your medical conditions, including: plans to have surgery; had surgery on your face; have trouble raising your eyebrows; drooping eyelids; any other abnormal facial change; are pregnant or plan to become pregnant (it is not known if BOTOX® Cosmetic can harm your unborn baby); are breast-feeding or plan to (it is not known if BOTOX® Cosmetic passes into breast milk).
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using BOTOX® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX® Cosmetic in the past.
Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc®, Dysport®, or Xeomin® in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; take aspirin-like products or blood thinners.
Other side effects of BOTOX® Cosmetic include: dry mouth; discomfort or pain at the injection site; tiredness; headache; neck pain; and eye problems: double vision, blurred vision, decreased eyesight, drooping eyelids and eyebrows, swelling of your eyelids and dry eyes.
For more information refer to the Medication Guide or talk with your doctor.
To report a side effect, please call Allergan at 1-800-678-1605.
Please see BOTOX® Cosmetic full Product Information including Boxed Warning and Medication Guide.
JUVÉDERM® Injectable Gel Fillers Important Information
APPROVED USES
JUVÉDERM® VOLUX® XC injectable gel is for deep injection to improve moderate to severe loss of jawline definition in adults over the age of 21.
JUVÉDERM® VOLUMA® XC injectable gel is for deep injection in the cheek area to correct age-related volume loss and for augmentation of the chin region to improve the chin profile in adults over 21.
JUVÉDERM® VOLLURE® XC, JUVÉDERM® Ultra Plus XC, and JUVÉDERM® Ultra XC injectable gels are for injection into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. JUVÉDERM® VOLLURE® XC injectable gel is for adults over 21.
JUVÉDERM® Ultra XC injectable gel is also for injection into the lips and perioral area for lip augmentation in adults over 21.
JUVÉDERM® VOLBELLA® XC injectable gel is for injection into the lips for lip augmentation and correction of perioral lines, and for injection into the undereye hollows to improve the appearance of undereye hollows in adults over the age of 21.
IMPORTANT SAFETY INFORMATION
Are there any reasons why I should not receive any JUVÉDERM® formulation?
Do not use these products if you have a history of multiple severe allergies or severe allergic reactions (anaphylaxis), if you are allergic to lidocaine or the Gram-positive bacterial proteins used in these products, or if you have had previous allergic reactions to hyaluronic acid fillers.
What warnings should my doctor advise me about?
- One of the risks with using dermal fillers is the unintentional injection into a blood vessel. The chances of this happening are very small, but if it does happen, the complications can be serious and may be permanent. These complications, which have been reported for facial injections, can include vision abnormalities, blindness, stroke, temporary scabs, or permanent scarring of the skin. Most of these events are irreversible.
- If you have changes in your vision, signs of a stroke (including sudden difficulty speaking, numbness or weakness in your face, arms or legs, difficulty walking, face drooping, severe headache, dizziness, or confusion), white appearance of the skin, or unusual pain during or shortly after treatment, you should notify your health care practitioner immediately.
- The use of dermal fillers where skin sores, pimples, rashes, hives, cysts, or infections are present should be postponed, as this may delay healing or make skin problems worse.
- The effectiveness of removal of any dermal filler has not been studied.
What precautions should my doctor advise me about?
- JUVÉDERM® VOLBELLA® XC should only be injected into undereye hollows by doctors who have completed the necessary training for this treatment area. To find a doctor, visit Juvederm.com/find-a-specialist. Doctors who complete the training will be listed with a symbol
- The safety of these products for use during pregnancy or while breastfeeding has not been studied
- The safety of JUVÉDERM® VOLUMA® XC has not been studied in patients under 35 years or over 65 years for cheek augmentation, under 22 years or over 80 years for chin augmentation.
- The safety of JUVÉDERM® VOLUX® XC, JUVÉDERM® VOLLURE® XC and JUVÉDERM® VOLBELLA® XC has not been studied in patients under 22 years, and the safety of JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC has not been studied in patients under 18 years
- The safety and effectiveness of treatment with JUVÉDERM® products in anatomical regions outside of their approved uses have not been established in clinical studies
- If you have a history of excessive scarring (thick, hard scars) or pigmentation disorders, treatment in these patients has not been studied and may result in additional scars or changes in pigmentation
- If you are planning other procedures including laser treatments or a chemical peel, there is a possible risk of inflammation at the treatment site if these procedures are performed closely before or after JUVÉDERM® injectable gel treatment
- Tell your doctor if you are on therapy used to reduce your body's natural defense system (such as steroids, chemotherapy, and medicines to treat autoimmune diseases, HIV, and AIDs), as these may increase your risk of infection; and medications that can prolong bleeding (such as aspirin, ibuprofen, or other blood thinners), as these may result in increased bruising or bleeding at the injection site.
- Avoid applying makeup for 12 hours after treatment and minimize strenuous exercise, exposure to extensive sun or heat, and alcoholic beverages within the first 24 hours following treatment, as these may cause temporary redness, swelling, and/or itching at the injection site
- JUVÉDERM® VOLUMA® XC was not studied in patients with significant loose skin of the chin, neck, or jaw
- The effect of JUVÉDERM® VOLUMA® XC injection into the chin on facial hair growth has not been studied
- Patients who experience skin injury near the site of JUVÉDERM® VOLUMA® XC injection may be at a higher risk for adverse events
- Tell your doctor if you have already been injected with dermal fillers in the same area as the one(s) you are about to be treated for. This information helps your doctor decide when and whether you should get treatment
What are possible side effects of treatment?
The most commonly reported side effects with JUVÉDERM® injectable gels were redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For JUVÉDERM® VOLBELLA® XC, dryness was also reported.
These side effects are consistent with other facial injection procedures and most will resolve within 30 days. Your doctor may choose to treat side effects persisting longer with antibiotics, steroids, or hyaluronidase (an enzyme that breaks down hyaluronic acid).
As with all skin injection procedures, there is a risk of infection.
To report a side effect with any product in the JUVÉDERM® Collection, please call the Allergan® Product Support Department at 18773455372. Please also visit Juvederm.com or talk to your doctor for more information.
Products in the JUVÉDERM® Collection are available only by a licensed physician or properly licensed practitioner.
References:
- Allergan Aesthetics. Market Research. Data on file. 2024.
- Allergan Aesthetics. Allē Payment Plans Pilot Program Insights. Data on file. 2024.
View original content to download multimedia:https://www.prnewswire.com/news-releases/introducing-all-payment-plans-powered-by-cherry-302183902.html
SOURCE AbbVie
FAQ
What are Allē Payment Plans by Allergan Aesthetics?
When did Allergan Aesthetics launch Allē Payment Plans?
How do Allē Payment Plans benefit aesthetic providers?
What were the results of the Allē Payment Plans pilot program?
How many Americans are interested in facial injectables according to market research?
What is the stock symbol for AbbVie?
